Breast Cancer in the Era of Precision Oncology: Molecular Pathogenesis, Integrated Diagnostics, and Therapeutic Advances

Breast cancer remains a major global health challenge because of its molecular heterogeneity, evolving patterns of therapeutic resistance, and persistent disparities in diagnosis and treatment. Although advances in molecular profiling and targeted therapies have improved patient management, translating these developments into durable and equitable clinical benefits remains difficult. This review provides an integrated analysis of breast cancer biology and precision oncology, linking molecular pathogenesis and tumour heterogeneity with diagnostic stratification, treatment selection, and mechanisms of therapeutic failure. It examines how histopathological classification, immunohistochemical biomarkers, genomic assays, liquid biopsy, and artificial intelligence can complement one another to support earlier detection, individualised risk assessment, and more informed therapeutic decisions. Established treatment modalities, including surgery, radiotherapy, chemotherapy, endocrine therapy, HER2-directed treatment, and immunotherapy, are discussed alongside emerging approaches such as antibody–drug conjugates, multi-omics integration, circulating tumour DNA-based minimal residual disease monitoring, therapeutic vaccines, epigenetic modulation, and genome editing. A central perspective of this review is that precision oncology requires more than identifying actionable molecular alterations: its effectiveness also depends on accounting for tumour evolution, intratumoral heterogeneity, resistance mechanisms, treatment-related toxicity, and the clinical validity of emerging biomarkers. Persistent challenges include the limited predictive value of some biomarkers, the need for prospective validation of novel diagnostic and monitoring tools, and unequal access to advanced technologies and therapies. Future priorities include developing robust predictive biomarkers, evaluating rational combination strategies, integrating longitudinal molecular monitoring into clinical decision-making, and ensuring that innovations are supported by rigorous clinical evidence and broader accessibility. A coordinated approach that integrates tumour biology, diagnostics, therapeutics, and patient-centred care is essential for advancing more durable, individualised, and equitable outcomes in breast cancer.